The Wall Street Journal: Valeant expected to name Paul Herendeen new CFO

Valeant Pharmaceuticals International Inc. is expected to announce it has hired Paul Herendeen as its new chief financial officer, luring the executive away from animal-health giant Zoetis Inc., according to sources close to the companies.

Herendeen, 60, would replace Robert Rosiello, who will remain with the Canadian pharmaceutical company as head of corporate development and strategy, according to the sources.

The hire, expected to be announced Monday morning, is a continuation of the shakeup at the embattled drugmaker. Valeant VRX, -1.54% named a new general counsel earlier this month, expanded its executive committee and gave some of its senior executives bigger roles.

>>> Original Source <<<